CAMBRIDGE, Mass. – January 8, 2024 – Flagship Pioneering, the bioplatform innovation company, today announced the formation of a new strategic initiative to foster enabling technologies for the life sciences and biotech sectors. The initiative will work with partners and across Flagship and its ecosystem of companies to accelerate the development of new therapeutic modalities by enabling and powering advanced technologies. Foundational to the new initiative is the formation and expansion of new partnerships, including with Thermo Fisher Scientific and announced today with Samsung C&T.
Flagship and Samsung C&T today announced the formation of an expanded partnership, leveraging ongoing cooperation between the two companies. As partners, Flagship and Samsung will support and advance bioplatform companies focused on groundbreaking technologies in translational science and medicine.
Flagship and Thermo Fisher recently announced the formation of a new strategic innovation partnership, which expands on the longstanding relationship between the companies. Through this transformative collaboration, Thermo Fisher and Flagship will work together to create new platform companies focusing on novel tools and capabilities that seek to power the biotech ecosystem and accelerate the development of first-in-class therapies. The partnership will leverage the expertise of both organizations including in the areas of life science tools, diagnostics, and services.
“We’re delighted to debut our new initiative to develop novel technologies, capabilities and services that empower the life sciences industry, made possible and accelerated by partnership,” said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering. “Core to the success of this new initiative will be collaboration with our partners, who are leaders in their respective fields and bring tremendous technological expertise and acumen. We envision this new initiative building on Flagship’s proven track-record in bioplatform innovation to power new technologies that generate bigger leaps for our ecosystem, our industry, and ultimately, for patients.”
Flagship debuts its new initiative at the 42nd annual J.P. Morgan Healthcare Conference, taking place from January 8-11, 2024 in San Francisco. Flagship Studio programming will feature Marc Casper, President and CEO, Thermo Fisher, and Jaywoo Kim, executive vice president, Samsung C&T. For a full schedule of Flagship Studio programming during the conference, please see here.
About Flagship Pioneering
Flagship Pioneering is a biotechnology company that invents and builds platform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $70 billion in aggregate value. To date, Flagship has deployed over $3.6 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including Denali Therapeutics (NASDAQ: DNLI), Foghorn Therapeutics (NASDAQ: FHTX), Generate:Biomedicines, Inari, Indigo Agriculture, Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB) and Tessera Therapeutics.